Lymphoma study group of JCOG
Lymphoma study group of JCOG
复制标题
JCOG淋巴瘤研究组
DOI：
10.1093/jjco/hyr168
复制
发表时间：
2012
期刊：
影响因子：
2.4
通讯作者：
Shimoyama M
中科院分区：
文献类型：
--
作者：
Tsukasaki K;Tobinai K;Hotta T;Shimoyama M
日本临床肿瘤学小组(JCOG)的淋巴瘤研究小组(LSG)于1978年由五个机构发起，目前有47名成员。JCOG-LSG专注于联合治疗方案、剂量强化和新药物的加入，以治疗淋巴系恶性肿瘤的主要疾病实体。针对侵袭性非霍奇金淋巴瘤(NHL)、成人T细胞白血病-淋巴瘤(ATL)、淋巴母细胞淋巴瘤/急性淋巴母细胞白血病(ALL)、霍奇金淋巴瘤(HL)、多发性骨髓瘤、NK/T-NHL和惰性B-NHL进行了30多个试验，包括10个随机试验，并对人类嗜T细胞病毒I型和T/B细胞表型进行了相关的流行病学和病理学研究。侵袭性NHL的首次试验显示，ATL、非ATL T-NHL和B-NHL的预后存在显著差异，建立了ATL的亚型，并导致了ATL和局限性鼻腔自然杀伤/T-NHL的标准治疗方法的建立。最近，对于包括弥漫性大B细胞淋巴瘤、套细胞淋巴瘤和惰性B-NHL在内的B-NHL，使用利妥昔单抗的方案已经被评估。JCOG-LSG治疗HL的试验导致达卡巴肼被批准用于日本的国家健康保险。JCOG-LSG结合分子靶向药物等新方法进行的多中心试验将有助于进一步改进淋巴系统恶性肿瘤的治疗。
The Lymphoma Study Group (LSG) of the Japan Clinical Oncology Group (JCOG) was initiated in 1978 by five institutions and now has 47 members. JCOG-LSG has focused on combined modalities, dose intensification and the incorporation of new agents for major disease entities of lymphoid malignancies. More than 30 trials including 10 randomized trials have been conducted for aggressive non-Hodgkin's lymphoma (NHL), adult T-cell leukemia–lymphoma (ATL), lymphoblastic lymphoma/acute lymphoblastic leukemia, Hodgkin's lymphoma (HL), multiple myeloma, NK/T-NHL and indolent B-NHL, and correlative epidemiological and pathological studies have been performed on human T-lymphotropic virus type-I and T/B cell phenotypes. The first trials for aggressive NHL revealed significant differences in the prognosis of ATL, non-ATL T-NHLs and B-NHLs, establishing a subclassification of ATL, and leading to the establishment of standard therapies for ATL and localized nasal natural killer/T-NHL. Recently, for B-NHLs including diffuse large B-cell lymphoma, mantle cell lymphoma, and indolent B-NHLs, regimens incorporating rituximab have been evaluated. The JCOG-LSG trials for HL led to the approval of dacarbazine for the National Health Insurance in Japan. The multicenter trials by the JCOG-LSG combining new modalities such as molecular-targeting agents will contribute to further improvements in the treatment of lymphoid malignancies.